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The effects of vagus nerve stimulation
on the course and outcomes of patients
with bipolar disorder in a treatment‑resistant
depressive episode: a 5‑year prospective
registry
R. Hamish McAllister‑Williams1,2* , Soraia Sousa1,2, Arun Kumar3, Teresa Greco3, Mark T. Bunker3,
Scott T. Aaronson4, Charles R. Conway5 and A. John Rush6,7,8

Abstract
Background: To compare illness characteristics, treatment history, response and durability, and suicidality scores
over a 5-year period in patients with treatment-resistant bipolar depression participating in a prospective, multicenter,
open-label registry and receiving Vagus Nerve Stimulation Therapy (VNS Therapy) plus treatment-as-usual (VNS + TAU)
or TAU alone.
Methods: Response was defined as ≥ 50% decrease from baseline Montgomery–Åsberg Depression Rating Scale
(MADRS) total score at 3, 6, 9, or 12 months post-baseline. Response was retained while MADRS score remained ≥ 40%
lower than baseline. Time-to-events was estimated using Kaplan–Meier (KM) analysis and compared using log-rank
test. Suicidality was assessed using the MADRS Item 10 score.
Results: At baseline (entry into registry), the VNS + TAU group (N = 97) had more episodes of depression, psychiatric
hospitalizations, lifetime suicide attempts and higher suicidality score, more severe symptoms (based on MADRS and
other scales), and higher rate of prior electroconvulsive therapy than TAU group (N = 59). Lifetime use of medications
was similar between the groups (a mean of 9) and was consistent with the severe treatment-resistant nature of their
depression. Over 5 years, 63% (61/97) in VNS + TAU had an initial response compared with 39% (23/59) in TAU. The
time-to-initial response was significantly quicker for VNS + TAU than for TAU (p < 0.03). Among responders in the first
year after implant, the KM estimate of the median time-to-relapse from initial response was 15.2 vs 7.6 months for
VNS + TAU compared with TAU (difference was not statistically significant). The mean reduction in suicidality score
across the study visits was significantly greater in the VNS + TAU than in the TAU group (p < 0.001).
Conclusions: The patients who received VNS + TAU included in this analysis had severe bipolar depression that had
proved extremely difficult to treat. The TAU comparator group were similar though had slightly less severe illnesses
on some measures and had less history of suicide attempts. Treatment with VNS + TAU was associated with a higher
likelihood of attaining a response compared to TAU alone. VNS + TAU was also associated with a significantly greater
mean reduction in suicidality.
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Limitations: In this registry study, participants were not randomized to the study treatment group, VNS Therapy
stimulation parameters were not controlled, and there was a high attrition rate over 5 years.
Trial registration ClinicalTrials.gov NCT00320372. Registered 3 May 2006, https://clinicaltrials.gov/ct2/show/NCT00
320372 (retrospectively registered)
Keywords: Bipolar disorder, Depression, Vagus Nerve Stimulation Therapy, VNS TRD registry, Response, Suicidality,
Treatment-resistant depression

Background
Patients with bipolar disorder are symptomatic about
50% of the time, the vast majority of which is depression (Judd et al. 2002, 2003). However, treatment options
for bipolar depression are limited. For example, the UK
National Institute for Health and Social Care (NICE)
guidelines for the management of bipolar depression list
just 3 treatments that are supported by replicated randomized controlled trials: lamotrigine, quetiapine, and
olanzapine (with or without fluoxetine) (National Institute for Health and Care Excellence 2014). Since publication of the NICE guidelines, additional evidence has
emerged from randomized controlled trials supporting
the efficacy of lurasidone for the acute treatment of bipolar depression (Loebel et al. 2014a, b). This limited number of treatment options for bipolar depression is further
compromised as quetiapine and olanzapine are often
poorly tolerated due to weight gain and sedation (Calabrese et al. 2005; Tohen et al. 2003).
The clinical challenge of managing bipolar depression
is further illustrated by observations of high rates of antidepressant usage (Kessing et al. 2016; Yoon et al. 2018)
despite evidence of questionable efficacy (National Institute for Health and Care Excellence 2014; Sidor and Macqueen 2011). The implication is that many patients suffer
from treatment-resistant bipolar depression (TRBD). The
prevalence of TRBD is unknown due to a lack of a consensus definition (Hidalgo-Mazzei et al. 2019). However,
it is known that about 50% and 30% of depressed bipolar
patients remain depressed at 6 and 12 months, respectively, following initiation of antidepressant treatment;
and the lack of treatment effects is due to non-response,
intolerance, or non-acceptance of treatment (Kupfer et al.
2000). As a result, TRBD is the major contributor to the
enormous burden of disease associated with bipolar disorder (Ferrari et al. 2016).
Given the significant unmet need with regards to the
management of bipolar depression, it is important that
alternative treatment options for patients with TRBD are
explored. One potential option is Vagus Nerve Stimulation Therapy (VNS Therapy).
VNS Therapy has primarily been examined in unipolar treatment-resistant depression (TRD). The largest
data set supporting its use in TRD is a 5-year VNS TRD

registry of nearly 500 participants (representing both
unipolar and bipolar TRD) who received adjunctive
VNS Therapy plus treatment-as-usual (VNS + TAU).
In this registry, the VNS-implanted TRD participants
were compared with 300 other TRD participants with
similar clinical presentations who received only TAU
(Aaronson et al. 2017). It is important to note that the
participants included in the registry were not randomized to VNS + TAU or TAU. Rather, treatment was
determined by a participant’s choice and availability of
VNS Therapy.
The data from the VNS TRD registry revealed that
the adjunctive VNS Therapy group had significantly
higher 5-year cumulative response (67.6% vs 40.9%)
and remission (43.3% vs 25.7%) rates compared to the
TRD patients who received TAU alone (Aaronson et al.
2017). Additionally, VNS + TAU led to a more durable
response as the time-to-relapse from initial response
for responders in the first year was 10.1 months versus 7.3 months for participants receiving TAU alone
(Kumar et al. 2019). Safety assessment in the registry
also found a greater reduction in suicidality in participants receiving VNS + TAU compared to TAU alone
(Aaronson et al. 2017).
Nierenberg and colleagues have previously described
the outcomes of 25 patients with TRBD who were
included in acute and long-term early studies of VNS
Therapy for the treatment of depression (Nierenberg
et al. 2008). The authors reported that the antidepressant efficacy outcomes for these TRBD patients were
similar to the unipolar TRD patients.
Benefit of VNS Therapy in patients with bipolar
disorder is also supported by a published case series
that included 5 patients who demonstrated sustained
improvement in depressive symptoms and a lack of
manic episodes during the follow-up period; and 3 of
these patients were followed for about 5 years (Oldani
et al. 2015).
In this report—using the 5-year VNS TRD registry discussed above—we examine the pre-treatment
clinical characteristics and the clinical outcomes in
a subgroup of TRD patients with TRBD comparing
VNS + TAU versus TAU alone based on the following
areas of interest:
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I. Illness characteristics and previous treatments
received prior to inclusion in the registry
II. Cumulative depressive symptom response (defined
by ≥ 50% reduction in Montgomery–Åsberg
Depression Rating Scale [MADRS]) over the 5-year
registry observation period
III. Duration of response (defined a priori as maintenance of ≥ 40% reduction from baseline MADRS)
IV. Change in suicidality score over the 5-year registry
observation period

Methods
Study population

Analysis of the 5-year VNS TRD registry data set
described here included 156 participants with bipolar
disorder (both bipolar I and II disorders): n = 97 received
VNS + TAU and n = 59 received TAU. To be eligible to
participate in the VNS TRD Registry, participants had
to be over 18 years of age, experiencing an active major
depressive episode of 2 years or longer in duration (either
unipolar or bipolar), or had a history of at least 3 major
depressive episodes, including the current depressive
episode, and a history of inadequate response to 4 or
more adequate antidepressant treatments (dosage per
Physicians’ Desk Reference labeling for a minimum of
4 weeks), which could include electroconvulsive therapy
(ECT). Participants could not have a history of a psychotic disorder or rapid-cycling bipolar disorder, or psychotic features in the present major depressive episode.
A more detailed list of study entry criteria can be found
elsewhere (Aaronson et al. 2017; Olin et al. 2012). ClinicalTrials.gov Identifier: NCT00320372.
Study treatment

Before enrollment into the VNS TRD Registry, participants could select the treatment group of their choice
(ie, TAU or VNS + TAU). The exception to this were
those VNS + TAU subjects who entered the registry
via rollover from a previous flexible dose-finding VNS
trial (Aaronson et al. 2013). Some participants could be
assigned to receive the alternate treatment by the site for
various reasons, including availability of surgical implantation at a site, number of allocated slots for implantation, or failure to qualify for insurance reimbursement or
VNS Therapy implantation. Device implantation surgery
and related medical care were covered either by a participant’s insurance policy or from personal funds.
Assessments

The assessment of the registry participants included in
this analysis has been detailed elsewhere (Aaronson et al.
2017). Participants in the VNS + TAU group underwent
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implantation during Visit 2 (baseline). Post-baseline follow-up visits for all participants were conducted at 3, 6, 9,
12, 18, 24, 30, 36, 42, 48, 54, and 60 months. The primary
measure of depression for this registry was the MADRS
(Carmody et al. 2006) which was administered by central
blinded raters. Other psychiatric outcome measures were
the Quick Inventory of Depressive Symptomatology–Self
Report (QIDS-SR) (Trivedi et al. 2004; Rush et al. 2003)
and the Clinical Global Impression (CGI) scale (Guy 1976).
Statistical analysis

The intent-to-treat (ITT) population included 195
registry participants with bipolar disorder (n = 134
VNS + TAU; n = 61 TAU) defined as those who completed their baseline visit, received their respective
treatment, and completed at least one post-baseline
assessment. To ensure consistent VNS Therapy dose
and follow-up schedule, the analysis sample excluded
individuals who were "crossed over" from VNS Therapy
treatment in the previously reported flexible dose study
(n = 37) since most of these participants had consistent
follow-up data for only 1 year (Aaronson et al. 2013). In
addition, we excluded participants who had a baseline
MADRS score < 10 indicating that they were already
remitted from their major depressive episode (Zimmerman et al. 2004); this excluded n = 2 from the TAU group.
The remaining 156 TRBD patients comprised of N = 97
receiving VNS + TAU and N = 59 receiving TAU and
were included in the analysis described here. Note that
participants who were crossed over to another treatment
group during the study were censored at the last visit
before cross-over.
Time-to-initial response was defined as the time from
baseline to the first visit when there was reduction in
MADRS score of ≥ 50% compared to baseline. A probability of time-to-initial response was estimated using
Kaplan–Meier (KM) method. KM probability estimates
were calculated for the time-to-event with 95% confidence intervals at 3, 6, 9, and 12 months. Time-to-event
curves for the 2 treatment groups were compared using
Log-rank test. A Cox proportional-hazard model was
used to estimate the hazard ratio (and 95% confidence
interval) of the instantaneous chance of a participant
having an event in the VNS + TAU group compared to
the TAU group at any given time during follow-up.
Given the different proportion of participants with
bipolar I or II disorder between the VNS + TAU and TAU
groups, a second Cox proportional-hazard model was
used to evaluate the time-to-first response, adjusting for
the effects of bipolar diagnosis and interaction between
treatment and bipolar diagnosis.
Persistence of response was defined as an ongoing reduction in MADRS score of ≥ 40% after an
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antidepressant response was recorded (reduction of
baseline MADRS of ≥ 50%). Persistence of response was
calculated for all study participants who had an initial
response in the first year of study treatment. Participants
were categorized in subgroups by the visit when the initial response occurred. A KM analysis was performed to
compare the retention of response in VNS + TAU and
TAU alone in a time-to-event analysis framework.
Participants were considered severely suicidal if they
had a score of ≥ 4 on MADRS Item 10. The percentage
who were still severely suicidal was calculated for each
post-baseline visit. Similarly, the percentage who were
non-severely suicidal at baseline who became severely
suicidal was calculated for each post-baseline visit. Average change in suicidality score for VNS + TAU and TAU
on MADRS Item 10 is presented for each post-baseline
visit.
If there were 1 or 2 consecutive missing data, then
the data was imputed with the average of the 2 adjacent
non-missing data. No imputation was done for 3 or more
consecutive missing data points. After imputation, participants were censored at the last visit with non-missing
data for all the analysis. Thus, there were a total of 412
visits with data for TAU group and 856 visits with data
for VNS + TAU group in the censored data set. Imputation for a single missed data point in the censored data
set was done for 32 visits (32/412 [7.8%]) of the available
data for TAU group and for 59 visits (59/856 [6.9%]) of
the available data for VNS + TAU group. Imputation for
2 consecutive missing data points was done for 14 visits (14/412 [3.4%]) of the available data for TAU group
and for 28 visits (28/856 [3.3%]) of the available data for
VNS + TAU group. Overall, there were 46 imputed data
(46/412 [11.2%]) of available data in TAU group and 87
imputed data (87/856 [10.2%]) of all available data) in
VNS + TAU group.
This imputation method has desirable properties as
detailed in Kumar et al. (2019). The data set has a regular
response pattern (when defined as reduction of MADRS
score of ≥ 50%), ie, the same response at the adjacent visits around one missing data: 78.1% for TAU and 62.7%
for VNS + TAU, and around 2 consecutive missing data
items: 100% for TAU and 78.1% for VNS + TAU. Thus,
occurrence of initial or second response could have been
altered due to imputation only for 1.7% of the censored
data for the TAU group and 3.3% of censored data in the
VNS + TAU group. Similarly, the censored data set provided a regular response pattern (when defined as reduction of MADRS score of ≥ 40%) around 1 missing data:
71.9% for TAU and 57.6% for VNS + TAU and around 2
consecutive missing data: 100% for TAU and 78.6% for
VNS + TAU. Thus, prolongation of the response maintenance could have occurred in only 2.2% of the censored
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data in the TAU group and 3.6% of the censored data in
the VNS + TAU group. Given this small percentage of
data that could have an altered response pattern due to
imputation, it was concluded that the imputation method
would work well for this data set and that it could not
have altered the result substantially in favor of any treatment group.

Results
Sample demographics and illness characteristics

Table 1 summarizes demographic information and baseline clinical characteristics for the analysis sample.
The age at onset of depressive symptoms (around
19–20 years of age) and age at initial diagnosis of an
episode of depression (around 8 years later) were similar between the groups. Overall, there were significantly
higher proportion of participants with a bipolar I diagnosis in the VNS + TAU group (n = 65 [67.0%] vs n = 28
[47.5%]) and lower rate of those with a bipolar II diagnosis (32 [33.0%] vs 31 [52.5%]) compared with the TAU
group (Chi-squared test for homogeneity, p = 0.0158).
The VNS + TAU group had experienced more episodes
of lifetime depressive episodes than the TAU group,
though this was not statistically significant. Moreover,
the VNS + TAU group had a history of more psychiatric
hospitalizations within the 5 years prior to entering the
registry and had more lifetime suicide attempts. Further,
the VNS + TAU subjects had greater depressive symptomology as assessed by the MADRS, QIDS-SR, and CGI.
Additionally, the VNS + TAU group scored significantly
higher on the suicidality item of the MADRS Item 10.
Treatment histories are presented in Table 2. There
was a very similar distribution of lifetime use of medications. The mean number of lifetime antidepressant treatment courses was approximately 9, with a maximum of
14 in both treatment groups. All study participants had
received antidepressants in the past or present, and selective serotonin reuptake inhibitors (SSRIs) and serotonin
and norepinephrine reuptake inhibitors (SNRIs) were the
most frequently prescribed antidepressant medication
classes. With regard to medications specifically recommended in guidelines for bipolar depression (National
Institute for Health and Care Excellence 2014), lamotrigine was the drug most commonly prescribed, followed
by quetiapine. About half of the VNS + TAU group had
taken lithium or sodium valproate, slightly more than
seen in the TAU group. Just over half of the VNS + TAU
group had prior ECT treatment, with a smaller number
in the TAU group (54% vs 39%). Most participants had
received psychological therapies, with a lifetime frequency of individual therapy being above 80% in both
groups.
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Table 1 Demographic and baseline clinical characteristics
VNS + TAU
(N = 97)
Mean age ± SD (years)

Female, n (%)

47.0 ± 10.2

72 (74.2%)

TAU
(N = 59)

P*

47.8 ± 10.6

0.65

47 (79.7%)

0.56

White, n (%)

93 (95.9%)

56 (94.9%)

1

Mean age ± SD at initial onset of depressive symptoms (years)

20.0 ± 11.5

18.9 ± 9.2

0.51

Mean age ± SD at initial diagnosis of depression (years)

Lifetime number of diagnosed depressive episode

Psychiatric hospitalizations within the 5 years prior to registry enrollment
Lifetime suicide attempts
DSM-IV-TR primary diagnosis, n (%)

26.9 ± 10.6

20.7 ± 29.2

3.6 ± 5.4

2.7 ± 4.8

27.9 ± 11.6

0.59

13.7 ± 23.2

0.10

1.5 ± 2.9

0.05
0.17

1.5 ± 2.1

< 0.001

Bipolar I disorder, currently moderately severe major depressive episode

19 (19.6%)

18 (30.6%)

Bipolar I disorder, currently severe major depressive episode

46 (47.4%)

10 (16.9%)

< 0.001

Bipolar II disorder, currently depressed

32 (33.0%)

31 (52.5%)

0.025

Baseline scores, n (%)
Montgomery–Åsberg Depression Rating Scale
Clinical Global Impression—Severity
Quick Inventory of Depressive Symptomatology-Self Report
Suicidality-based on MADRS Item 10

33.7 ± 7.3

5.2 ± 0.8

18.4 ± 4.9

2.7 ± 1.4

29.7 ± 5.9

< 0.001

4.7 ± 0.7

< 0.001

15.9 ± 5.2

0.004

2.0 ± 1.2

0.003

SD standard deviation
* P-values are from two-sided t-test for comparing means assuming unequal variance or z-test for comparing proportions

Table 2 Lifetime treatment histories
VNS + TAU (N = 97)

TAU (N = 59)

Number of treatment courses*
Mean

9.2

9.0

Maximum

14

14

Minimum
Antidepressants, n (%)

3

4

97 (100%)

59 (100%)

Bupropion

71 (73%)

38 (64%)

Selective serotonin reuptake inhibitors (SSRIs)

88 (91%)

50 (85%)

Serotonin and norepinephrine reuptake inhibitors (SNRIs)

78 (80%)

48 (81%)

Other

68 (70%)

35 (59%)

Antipsychotics, anticonvulsants, and other medications, n (%)
Lamotrigine

62 (64%)

44 (75%)

Quetiapine

56 (58%)

35 (59%)

Olanzapine

37 (38%)

24 (24%)

Olanzapine + fluoxetine

5 (5%)

6 (10%)

Lithium

53 (55%)

25 (42%)

Sodium valproate

54 (56%)

20 (34%)

53 (54%)

23 (39%)

Electroconvulsive therapy, n (%)
Psychological therapies, n (%)
Cognitive behavioral therapy (CBT)

44 (45%)

23 (39%)

Individual therapy

83 (86%)

48 (81%)

* A course of treatment was defined as at least a 4-week continuous period in which a patient used one or more treatments for their depression. A new course of
treatment started each time a drug was added or dropped. Courses of treatment were classified as electroconvulsive therapy, monotherapy, combination therapies,
augmentation therapies, or other psychiatric treatments
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The Cox proportional-hazard model on time-to-first
response adjusting for the effects of bipolar diagnosis
and the correspondent interaction, confirmed the benefit of VNS + TAU in reducing the time-to-first response
(HR = 1.6; 95% CI 0.98, 2.7) and VNS + TAU showed
trends of effectiveness in both sub-populations (HR = 2.1
in bipolar I and HR = 1.3 in bipolar II, even if a significant treatment effect of VNS + TAU vs TAU was seen
just in the participants with bipolar I (95% CI 1.0, 4.3)
(Table 3). This may in part be driven by the smaller number of patients with bipolar II vs bipolar I disorder (n = 59
vs n = 97) and the low rate of responses in the bipolar II
subgroup (n = 17 vs n = 14 for the VNS + TAU and TAU
groups, respectively). Due to the low rate, it was also
not possible to estimate the 95% confidence intervals in
KM analysis for the median time-to-first response in the
bipolar II patients (Table 4).

Cumulative response rates

Over the 5-year observation period, 61 of 97 (63%) in
the VNS + TAU group had an initial response (defined
as ≥ 50% reduction in MADRS from baseline) compared to 23 of 59 (39%) of participants in the TAU
group. The KM plot in Fig. 1 shows that time-to-initial response was significantly shorter for VNS + TAU
than for TAU alone (p = 0.03 for log-rank test). The
estimated cumulative probability for the time-to-initial response was higher for the VNS + TAU group
as compared to the TAU group over most of the follow-up period. Median time-to-initial response was
13.7 month (Q1 = 5, Q3 = 37.7) for VNS + TAU group
compared to 42.1 months (Q1 = 8.3, Q3 = not estimable) for TAU group. Hazard ratio for time-to-initial
response for VNS + TAU compared to TAU was 1.7
(95% CI 1, 2.7) meaning a larger chance for a participant in the VNS + TAU group to get an initial response
compared to a participant in the TAU group at any
given time during the follow-up, though the hazard
ratio was not statistically significant.

Duration of response

Maintenance of response was defined a priori as maintenance of ≥ 40% reduction from baseline MADRS

Participants with available response data by visit (month, m)
Treatment
group

0m

6m

12 m

18 m

24 m

30 m

36 m

42 m

48 m

54 m

60 m

VNS+TAU

97

65

42

31

23

19

16

12

11

9

7

TAU

59

43

27

16

14

13

12

11

8

6

3

Fig. 1 Kaplan–Meier plot for time-to-initial response based on MADRS score
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Table 3 Cox proportional-hazards model examining effect
of bipolar diagnosis on the time-to-first response
Effect
VNS + TAU vs TAU

Hazard ratio 95% CI
95% CI
p-value
lower limit upper limit
1.6

0.98

2.7

0.06

Bipolar II vs
bipolar I

0.96

0.6

1.6

0.9

VNS vs TAU in
bipolar I

2.1

1.0

4.3

0.04

VNS vs TAU in
bipolar II

1.3

0.6

2.6

0.5

and assessed in those who showed a response in the
first year of follow-up. In the VNS + TAU group, 46 of
the 61 responders (75.4%) responded in the first year;
and in the TAU group, 19 of the 23 responders (82.6%)
responded in the first year. Numbers are small and
hence comparisons between the 2 groups may not be
robust.
A KM analysis of the data estimated that the
median time-to-relapse from initial response in the
first year was 15.2 months (Q1 = 6.7, Q3 = 25.4) for
the VNS + TAU group compared with 7.6 months
(Q1 = 3.4, Q3 = 14.7) for the TAU group. The hazard
ratio for relapse after the initial response was 0.7 (95%
CI 0.3, 1.4) in favor of VNS, though this was not statistically significant. In terms of actual data, it was possible to examine maintenance of response 6 months
after initial response in participants who demonstrated an initial response at the 3-, 6-, or 12-month
study visits. Of these, 30/39 (76.9%) in the VNS + TAU
group were maintaining a response 6 months later,
compared with 10/18 (55.6%) in the TAU group. There
was limited data to examine maintenance of response
12 months after initial response since this was only
available for those who showed an initial response at
the 6- or 12-month visits. However, again, the proportion maintaining a response was numerically higher
in the VNS + TAU compared with TAU group (6/13
[46.1%] vs 3/11 [27.3%], respectively).

Suicidality

A total of 33 (33/97; 34%) in the VNS + TAU group and
8 (8/59; 14%) in the TAU group were severely suicidal
at baseline based on MADRS (a score ≥ 4 on MADRS
Item 10 corresponding to the responses “probably better
off dead” and “active preparations for suicide”). Notably,
the mean reduction in suicidality score across the study
visits was significantly greater in the VNS + TAU than in
the TAU group (P < 0.001 as per F-test) (Fig. 2).
In each treatment group, the percentage who became
severely suicidal post-baseline was less than 15% (Table 5)
and the difference between the treatment groups was not
statistically significant.

Discussion
Given the frequency of TRBD and its impact on patients
with bipolar disorder, it is important to consider all possible treatment options. This post-hoc analysis suggests
that in a non-randomized study following the outcomes
of patients with TRBD for up to 5 years, the addition of
VNS Therapy to TAU had significantly greater cumulative
response rates, faster onset of antidepressant response,
and the responses were longer in duration than in participants receiving TAU alone. Critically, VNS + TAU
was also associated with a significantly greater reduction
in suicidal ideation compared with TAU alone, despite
the VNS + TAU group being more severely depressed
at baseline and with high ratings of suicidality. These
findings are consistent with the observations made in a
much larger group of patients with unipolar or bipolar
depression (Aaronson et al. 2017). They are also consistent with a previous post-hoc analysis of 25 patients with
TRBD who made up 11% of a larger TRD population
who received VNS Therapy alongside TAU in a shamcontrolled acute study with long-term open-label followup (Nierenberg et al. 2008). The only other study of the
safety and efficacy of VNS Therapy in bipolar disorder
is a 1-year pilot study of VNS Therapy in 9 patients with
rapid cycling bipolar disorder that did not have a comparator group (Marangell et al. 2008).
These findings suggest that VNS Therapy may be effective in patients with very significant difficult to treat

Table 4 Kaplan–Meier estimates for time-to-first response, months
First quartile (95% CI)

Median (95% CI)

Third quartile (95% CI)

Bipolar 1
VNS + TAU

TAU

5.8 (4.1, 7.7)
13.1 (4, 37)

13 (7.7, 23.2)

36.6 (23.2, NE)

37 (13.1, NE)

NE (37, NE)

Bipolar 2
VNS + TAU

TAU

CI confidence interval, NE not estimable

4.7 (3.7, 10.4)

19.5 (9.2, NE)

NE (24.8, NE)

7.9 (4.3, 13.2)

14.3 (8.3, NE)

NE (48.8, NE)
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Fig. 2 Mean change in suicidality score from baseline based on MADRS Item 10

depression in the context of bipolar disorder. Those
treated with VNS Therapy had an average of 20.7 lifetime episodes of depression, 3.6 psychiatric hospitalizations in the previous 5 years, and 2.7 lifetime suicide
attempts. They had received an average of 9 mediation treatment courses over their lifetime and all had
received an antidepressant, despite the lack of evidence
that these are efficacious in patients with bipolar disorder
(Sidor and Macqueen 2011; Young et al. 2010). The vast
majority had also received psychotherapy, and about half
(54%) had been treated with ECT. Importantly, despite
the VNS + TAU participants having considerably more
severe depressive histories (statistically significantly more
severe depressive symptomology and greater suicidal
ideation at baseline prior to treatment), the VNS + TAU
group demonstrated superior antidepressant outcomes.
The magnitude of the effect on cumulative response
rates with VNS + TAU versus TAU was slightly larger
than that seen in patients with unipolar depression in

the original analysis of this data set (Aaronson et al.
2017). However, the assessment of the impact of VNS
Therapy on durability of response in this current analysis is not as great as that seen in the unipolar patients
studied as part of this registry (Kumar et al. 2019).
This is perhaps not surprising given that bipolar disorder is more recurrent than unipolar disorder (Angst
et al. 2003). While there was no significant difference
in durability of response between the VNS + TAU and
TAU groups in this analysis, numerically the participants receiving VNS + TAU did better. The lack of significant findings with regards to durability of response
may have in part arisen due to the small numbers
of patients included in the analysis, particularly at
later visit time points, and the relative infrequency of
assessment of mood symptoms. Given the importance
of prophylaxis in a recurrent disorder such as bipolar
disorder, further research investigating the prophylactic efficacy of VNS Therapy is indicated, including in
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Table 5 Change in suicidal rating from non-severe
to severe based on MADRS Item 10
Visit months

VNS + TAU

TAU

3

3/57 (5.3%)

3/44 (6.8%)

6

2/49 (4.1%)

4/40 (10%)

9

1/43 (2.3%)

2/32 (6.3%)

12

6/44 (13.6%)

2/28 (7.1%)

18

1/39 (2.6%)

1/22 (4.5%)

24

0/36 (0%)

0/19 (0%)

30

1/29 (3.4%)

0/14 (0%)

36

1/30 (3.3%)

0/16 (0%)

42

1/28 (3.6%)

1/15 (6.7%)

48

2/27 (7.4%)

1/18 (5.6%)

54

1/18 (5.6%)

1/10 (10%)

60

2/23 (8.7%)

0/14 (0%)

The numerator denotes the number of participants who had a non-severe
suicidal rating at baseline (score < 4) and developed a severe suicidal rating
(score ≥ 4) at a post-baseline visit based on MADRS Item 10. The denominator
denotes the number of participants who had a non-severe suicidal rating at
baseline and attended a post-baseline visit

patients with rapid cycling, utilizing frequent assessments of symptoms.
Previous analyses in a mixed, but predominantly unipolar TRD population, have suggested a reduction in
rates of suicide and all-cause mortality associated with
VNS treatment (Aaronson et al. 2017; Feldman et al.
2013). The significant reductions in suicidality seen in
this post-hoc analysis of patients with TRBD treated
with VNS Therapy suggests that such findings might
be expected in a larger population of individuals with
TRBD, though further research is required. Similarly, it
is important to further explore whether the cost effectiveness of VNS Therapy, observed in mixed TRD populations (predominantly unipolar depression), will also
be observed in TRBD patients (Feldman et al. 2013).
VNS Therapy is generally well tolerated as revealed in
a meta-analysis of over 1000 patients with either unipolar or bipolar depression (Berry et al. 2013). Data
regarding the impact of adverse effects of medication
was not available in the specific sub-sample of bipolar patients reported here. However, in the complete
sample of unipolar and bipolar patients in the registry study (Aaronson et al. 2017), medication adverse
effects were assessed using the frequency, intensity,
and burden of side effects rating (FIBSER) scale (Wisniewski et al. 2006). Based on this scale, the patients in
the VNS + TAU group reported higher scores for frequency, severity, and burden of side effects at baseline,
but at the 12 and 24 months timepoints, there were no
significant differences between the groups (data available on request).

There was a significant difference in the proportion of bipolar I participants in the two groups (67%
in TAU + VNS vs 47% in TAU) and it is possible that
this, in part, impacted the results. A significant effect
of VNS + TAU over TAU was seen for time-to-first
response in bipolar I participants (HR = 2.1; 95% CI 1,
4.3). This was not evident in those with bipolar II disorder, though the event rate was such that it is not possible
to draw meaningful conclusions regarding a bipolar I vs
bipolar II difference in the effectiveness of VNS Therapy
added to TAU. In addition, this registry study unfortunately did not collect formal ratings of manic symptoms,
so it is not possible to infer the effects of VNS Therapy on
elevated mood. A previous 12-month follow-up study of
VNS Therapy that included 20 patients with bipolar disorder assessed manic symptoms (Rush et al. 2005). Two
of the participants developed brief mild manic episodes
that lasted 1 to 2 weeks, and there were two short periods of sub-syndromal hypomanic symptoms (about 1 to
3 days), during the first 3 months of treatment with VNS
Therapy. One participant (with a baseline diagnosis of
unipolar disorder) developed a manic episode during the
subsequent 9 months of treatment with VNS Therapy.
Additional data are required to address whether there are
potential differential effects between bipolar I vs II and
the effect of VNS Therapy on hypomanic/manic symptoms, and such data will hopefully become available following completion of the current ongoing RECOVER
randomized trial in the USA and the RESTORE-LIFE
registry in Europe.
The study had several additional limitations. Participants were not randomized to the treatment groups, and
when VNS Therapy was an available treatment option,
there appeared to be a tendency for the treatment to be
utilized in patients with bipolar disorder who had a significant degree of pharmacological non-response (or
intolerance) and who had a higher rate of ECT treatment history (54%). This rate of ECT usage is similar to
that seen in the unipolar patients included in the registry
(61%) who received VNS. In addition, there was no sham
VNS for the “TAU” group. Therefore, it is not possible to
conclude with high certainty that all the effects observed
are exclusively related to treatment with adjunctive
VNS Therapy. The higher baseline MADRS score in the
VNS + TAU compared with TAU group might also mean
that regression to the mean may have played a larger
role in the VNS + TAU group. In this effectiveness trial,
medications and all other treatments, such as TMS and
ECT, could change during treatment for either treatment
group. Furthermore, study participants and clinicians
were knowledgeable about the care being given. However, the off-site central raters collecting the MADRS
data were blind to both treatment group and the overall
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clinical status of the study participants. The population
examined limits generalizability, though it is of course
reasonably representative of participants suffering from
a significant degree of difficult to treat depression in the
context of bipolar disorder. Suicidality was not assessed
using a specific suicidality scale, but rather a single item
in the MADRS. Finally, in this 5-year longitudinal study,
the participant attrition over time limits our ability to
address with significant sample sizes some of the questions that are posed.

Conclusions
VNS Therapy as an adjunctive treatment to TAU was
more effective than TAU alone in reducing depressive
symptomatology, and led to a greater reduction in suicidal ideation, and, on average, a more rapid antidepressant response. Further, the antidepressant effects
observed in the VNS + TAU group vis-à-vis TAU were
likely more durable. Together, these findings support
previously observed findings that adjunctive VNS is
an efficacious antidepressant treatment in very severe,
treatment-resistant bipolar depression.
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